For Patients / Support
If you've been prescribed MVASI®, you might have questions about how your medicine may be covered by your insurance. That’s why we created Amgen Assist 360™—to support you in every way we can, so you can focus on what’s most important to you.
Whatever type of insurance you have—even if you have none—your Amgen Reimbursement Counselor can help you understand how MVASI® may be covered, and refer you to programs that may be able to help you afford it, such as Amgen FIRST STEP™.
To speak to an Amgen Reimbursement Counselor call: 1-888-4ASSIST (888-427-7478) or visit AmgenAssist360.com.
Amgen Reimbursement Counselors can help you understand:
REFERRALS TO RESOURCES FOR DAY-TO-DAY LIVING*
We can help refer you to independent nonprofit organizations that may provide you with community resources, one-on-one counseling services, and local support groups.
The Amgen FIRST STEP™ Program can help eligible commercially insured patients cover their out-of-pocket prescription costs, including deductible, co-insurance, and co-payment.†
Monday to Friday • 9:00 am to 8:00 pm ET
or visit AmgenFIRSTSTEP.com.
The Amgen FIRST STEP™ Prepaid MasterCard is issued by Comerica Bank pursuant to license by MasterCard International Incorporated. No cash or ATM access. MasterCard is a registered trademark of MasterCard International Incorporated. This card can be used only to cover the co-payment for eligible prescriptions covered under the program at participating merchant locations where Debit MasterCard is accepted.
FOR INFORMATION SPECIFIC TO YOUR DIAGNOSIS, PLEASE MAKE A SELECTION BELOW
VISIT THESE WEBSITES FOR MORE INFORMATION ABOUT VARIOUS CANCERS
*Resources include referrals to independent nonprofit patient assistance programs. Eligibility for resources provided by independent nonprofit patient assistance programs is based on the nonprofits’ criteria. Amgen has no control over these programs and provides referrals as a courtesy only.
†Terms, conditions, and program maximums apply. This program is not open to patients receiving prescription reimbursement under any federal, state, or government-funded healthcare program. Not valid where prohibited by law.
Important Safety Information
Possible serious side effects
Everyone reacts differently to MVASI® therapy. So, it's important to know what the side effects are. Although some people may have a life-threatening side effect, most do not. Your doctor will stop treatment if any serious side effects occur. Be sure to contact your health care team if there are any signs of these side effects.
Side effects seen most often
In clinical studies across different types of cancer, some patients experienced the following side effects:
MVASI® is not for everyone
Talk to your doctor if you are:
For more information about your treatment or condition, talk to your doctor.
You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Amgen at 1-800-772-6436.
Please see full Product Information for additional Important Safety Information.
Metastatic Colorectal Cancer (mCRC)
MVASI® is approved to treat metastatic colorectal cancer (mCRC) for:
MVASI® is not approved for use after the primary treatment of colon cancer that has not spread to other parts of the body.
Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
MVASI®, in combination with carboplatin and paclitaxel, is approved to treat advanced non-squamous non-small cell lung cancer (NSCLC) in people who have not received chemotherapy for their advanced disease.
Recurrent Glioblastoma (rGBM)
MVASI® is approved to treat recurrent glioblastoma in adults.
Metastatic Renal Cell Carcinoma (mRCC)
MVASI®, used with interferon alfa, is approved to treat metastatic kidney cancer (mRCC).
Advanced Cervical Cancer (CC)
MVASI®, in combination with paclitaxel and cisplatin or paclitaxel and topotecan, is approved to treat persistent, recurrent, or metastatic cancer of the cervix.
Ovarian Cancer (OC)
MVASI®, in combination with carboplatin and paclitaxel, followed by Avastin alone, is used for the treatment of patients with advanced (Stage III or IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgery.
MVASI®, in combination with paclitaxel, pegylated liposomal doxorubicin or topotecan, is approved to treat platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer in women who received no more than two prior chemotherapy treatments.
MVASI®, either in combination with carboplatin and paclitaxel or with carboplatin and gemcitabine, followed by Avastin alone, is approved for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.